Phenylbutazone

Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS) . Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID) . Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].

Product Specifications

CAS Number

[50-33-9]

UNSPSC

12352005

Hazard Statement

H301, H312+H332, H315, H319, H335

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/phenylbutazone.html

Purity

99.82

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

Smiles

O=C(C1CCCC)N(C2=CC=CC=C2)N(C3=CC=CC=C3)C1=O

Molecular Formula

C19H20N2O2

Molecular Weight

308.37

Precautions

H301, H312+H332, H315, H319, H335

References & Citations

[1]Beretta C, et al. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52 (4) :302-6.|[2]G A Reed, et al. Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism. Mol Pharmacol. 1985 Jan;27 (1) :109-14.|[3]Guiying Chen, et al. Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy. Sci Rep. 2016 Apr 29;6:25317.